0001144204-18-027302.txt : 20180511 0001144204-18-027302.hdr.sgml : 20180511 20180511090103 ACCESSION NUMBER: 0001144204-18-027302 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180511 DATE AS OF CHANGE: 20180511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellectar Biosciences, Inc. CENTRAL INDEX KEY: 0001279704 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043321804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36598 FILM NUMBER: 18825056 BUSINESS ADDRESS: STREET 1: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 BUSINESS PHONE: (608) 441-8120 MAIL ADDRESS: STREET 1: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 FORMER COMPANY: FORMER CONFORMED NAME: NOVELOS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20050617 FORMER COMPANY: FORMER CONFORMED NAME: COMMON HORIZONS INC DATE OF NAME CHANGE: 20040211 10-Q 1 tv492649_10q.htm 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

[mark one]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2018

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission File Number 1-36598

CELLECTAR BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

DELAWARE

04-3321804

(State or other jurisdiction of
incorporation or organization)

(IRS Employer

Identification No.)

3301 Agriculture Drive

Madison, Wisconsin 53716

(Address of principal executive offices)

(608) 441-8120

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨

Non-accelerated filer	¨(Do not check if a smaller reporting company)	Smaller reporting company	x

		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Number of shares outstanding of the issuer’s common stock as of the latest practicable date: 17,388,344 shares of common stock, $0.00001 par value per share, as of May 7, 2018.

CELLECTAR BIOSCIENCES, INC.

FORM 10-Q INDEX

	Forward-Looking Statements	3

PART I. FINANCIAL INFORMATION		4

Item 1.	Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 4.	Controls and Procedures	18

PART II. OTHER INFORMATION		20

Item 1.	Legal Proceedings	20
Item 1A.	Risk Factors	20
Item 6.	Exhibits	22

This quarterly report on Form 10-Q of Cellectar Biosciences, Inc. (the “Company”, “Cellectar”, “we”, “us”, “our”) contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. Examples of our forward-looking statements include:

our current views with respect to our business strategy, business plan and research and development activities;

the progress of our product development programs, including clinical testing and the timing of commencement and results thereof;

our projected operating results including research and development expenses;

our ability to continue development plans for CLR 131, CLR 1700 series, CLR 1800 series, CLR 1900 series, CLR 2000 series, CLR 2100 series and CLR 2200 series;

our ability to maintain orphan drug designation in the United States for CLR 131 as a therapeutic for the treatment of multiple myeloma, neuroblastoma and rhabdomyosarcoma, and the expected benefits of orphan drug status;

our ability to pursue strategic alternatives;

our ability to further our technologies into product candidates;

our consumption of current resources and ability to obtain additional funding;

our current view regarding general economic and market conditions including our competitive strengths; and

assumptions underlying any of the foregoing; and any other statements that address events or developments that we intend or believe will or may occur in the future.

In some cases, you can identify forward-looking statements by terminology, such as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “believes,” “seeks,” “may,” “should”, “could” or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Forward-looking statements also involve risks and uncertainties, many of which are beyond our control. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus.

You should read this report completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this report is accurate as of the date hereof only. Because the risk factors referred to herein could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this prospectus and any accompanying prospectus supplement, and particularly our forward-looking statements, by these cautionary statements.

This quarterly report on Form 10-Q contains trademarks and service marks of Cellectar Biosciences, Inc. Unless otherwise provided in this quarterly report on Form 10-Q, trademarks identified by ™ are trademarks of Cellectar Biosciences, Inc. All other trademarks are the properties of their respective owners.

PART I. FINANCIAL INFORMATION

Item 1.

Financial Statements

CELLECTAR BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2018 (Unaudited)			December 31, 2017
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	6,820,163		$	10,006,421
Restricted cash		55,000			55,000
Prepaid expenses and other current assets		770,012			877,996
Total current assets		7,645,175			10,939,417
FIXED ASSETS, NET		228,836			244,713
GOODWILL		1,675,462			1,675,462
OTHER ASSETS		11,872			11,872
TOTAL ASSETS	$	9,561,345		$	12,871,464

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	$	1,883,783		$	1,867,758
Derivative liability		132,000			105,050
Deferred rent		88,964			138,944
Capital lease obligations, current portion		3,119			3,036
Total current liabilities		2,107,866			2,114,788
LONG-TERM LIABILITIES:
Capital lease obligation, less current portion		1,402			2,213
Total long-term liabilities		1,402			2,213
TOTAL LIABILITIES		2,109,268			2,117,001
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.00001 par value; 7,000 shares authorized; Series B preferred stock; 11.5 and 18 issued and outstanding as of March 31, 2018 and December 31, 2017 respectively		637,017			995,782
Common stock, $0.00001 par value; 80,000,000 shares authorized; 17,101,676 and 16,661,446 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively		171			167
Additional paid-in capital		94,640,028			94,107,830
Accumulated deficit		(87,825,139	)		(84,349,316	)
Total stockholders’ equity		7,452,077			10,754,463
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	9,561,345		$	12,871,464

The accompanying notes are an integral part of these condensed consolidated financial statements.

CELLECTAR BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended March 31,
	2018			2017

COSTS AND EXPENSES:
Research and development	$	2,124,060		$	1,856,880
General and administrative		1,329,467			955,356
Total costs and expenses		3,453,527			2,812,236

LOSS FROM OPERATIONS		(3,453,527	)		(2,812,236	)

OTHER INCOME (EXPENSE):
Loss on revaluation of derivative warrants		(26,950	)		(82,475	)
Interest income, net		4,654			3,387
Total other income (expense), net		(22,296	)		(79,088	)
NET LOSS	$	(3,475,823	)	$	(2,891,324	)
BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE	$	(0.21	)	$	(0.24	)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE		16,808,189			12,010,284

The accompanying notes are an integral part of these condensed consolidated financial statements.

CELLECTAR BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Three Months Ended March 31,
	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,475,823	)	$	(2,891,324	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization		17,301			86,911
Stock-based compensation expense		173,438			165,674
Loss on revaluation of derivative warrants		26,950			82,475
Changes in:
Accounts payable and accrued liabilities		16,025			(230,341	)
Prepaid expenses and other current assets		107,984			(199,616	)
Other assets and liabilities		(49,980	)		(1,216	)
Cash used in operating activities		(3,184,105	)		(2,987,437	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of fixed assets		(1,425	)		(66,301	)
Cash used in investing activities		(1,425	)		(66,301	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of warrants		—			2,934,759
Payments on notes payable		—			(86,591	)
Payments on capital lease obligations		(728	)		(655	)
Cash (used in) provided by financing activities		(728	)		2,847,513
NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH		(3,186,258	)		(206,225	)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT BEGINNING OF PERIOD		10,061,421			11,444,619
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF PERIOD	$	6,875,163		$	11,238,394
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest expense	$	—		$	364

The accompanying notes are an integral part of these condensed consolidated financial statements.

CELLECTAR BIOSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN

The Company is subject to a number of risks similar to those of other small pharmaceutical companies. Principal among these risks are the need to obtain additional financing necessary to fund future operations, dependence on key individuals, competition from substitute products and larger companies and the successful development and marketing of its products in a highly regulated environment.

The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has devoted substantially all its efforts toward research and development and has, during the three months ended March 31, 2018, generated an operating loss of approximately $3,454,000. The Company expects that it will continue to generate operating losses for the foreseeable future.

The Company believes that its cash balance at March 31, 2018 is adequate to fund operations into early first quarter 2019. The Company’s ability to execute its operating plan beyond early first quarter 2019 depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. The Company plans to continue to actively pursue financing alternatives, but there can be no assurance that it will obtain the necessary funding, raising substantial doubt about the Company’s ability to continue as a going concern within one year of the date these financial statements are issued. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The accompanying condensed consolidated balance sheet as of December 31, 2017 has been derived from audited financial statements. The accompanying unaudited condensed consolidated balance sheet as of March 31, 2018, the condensed consolidated statements of operations for the three months ended March 31, 2018 and 2017, the condensed consolidated statements of cash flows for the three months ended March 31, 2018 and 2017 and the related interim information contained within the notes to the condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions, rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all the information and the notes required by U.S. GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments which are of a nature necessary for the fair presentation of the Company’s consolidated financial position at March 31, 2018 and consolidated results of its operations and cash flows for the three months ended March 31, 2018 and 2017. The results for the three months ended March 31, 2018 are not necessarily indicative of future results.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes thereto included in the Company’s Form 10-K for the fiscal year ended December 31, 2017, which was filed with the SEC on March 21, 2018.

Principles of Consolidation — The consolidated financial statements include the accounts of the Company and the accounts of its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

Restricted Cash — The Company accounts for cash that is restricted for other than current operations as restricted cash. Restricted cash at March 31, 2018 and December 31, 2017 consisted of a certificate of deposit of $55,000 required under the Company’s lease agreement for its Madison, Wisconsin facility.

Goodwill — Goodwill is not amortized but is required to be evaluated for impairment annually or whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company evaluates goodwill for impairment annually in the fourth fiscal quarter and additionally on an interim basis if an event occurs or there is a change in circumstances, such as a decline in the Company’s stock price or a material adverse change in the business climate, which would more likely than not reduce the fair value of the reporting unit below its carrying amount. No such event or change in circumstances occurred; therefore, no changes in goodwill were made during the three months ended March 31, 2018 and 2017.

In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill. The standard streamlines the methodology for calculating whether goodwill is impaired based upon whether the carrying amount of goodwill exceeds the reporting unit’s fair value. ASU 2017-04 applies to public business entities and those other entities that have goodwill reported in their financial statements and have not elected the private company alternative for the subsequent measurement of goodwill and is effective for annual and interim reporting periods beginning after December 15, 2019, with early adoption permitted. The Company does not expect that the adoption of this standard will have a material effect on its financial statements.

Impairment of Long-Lived Assets — Long-lived assets other than goodwill consist primarily of fixed assets, which we periodically evaluate for potential impairment. Whenever events or circumstances change, an assessment is made as to whether there has been an impairment in the value of long-lived assets by determining whether projected undiscounted cash flows generated by the applicable asset exceed its net book value as of the assessment date. No such event or change in circumstances occurred; therefore, no such impairment occurred during the three months ended March 31, 2018 and 2017.

Stock-Based Compensation — The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for awards that are not performance-based is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Awards of stock that are not performance-based are valued at the fair market value on the date of the grant and are amortized over the service period of the award. Non-employee stock-based compensation is accounted for in accordance with the guidance of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) Topic 505, Equity. As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.

Fair Value of Financial Instruments — The guidance under FASB ASC Topic 825, Financial Instruments, requires disclosure of the fair value of certain financial instruments. Financial instruments in the accompanying financial statements consist of cash equivalents, accounts payable and long-term obligations. The carrying amount of cash equivalents and accounts payable approximate their fair value because of their short-term nature. The carrying value of remaining long-term obligations, including the current portion, approximates fair value because the fixed interest rate approximates current market interest rates available on similar instruments.

Derivative Instruments — The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain a certain type of cash settlement feature, “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was 494,315 and 533,065 at March 31, 2018 and December 31, 2017 respectively. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At March 31, 2018 and December 31, 2017, these warrants represented the only outstanding derivative instruments issued or held by the Company.

Leases — In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for in a similar fashion to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is currently evaluating the method of adoption and the impact of adopting ASU 2016-02 on its results of operations, cash flows and financial position.

Recent Accounting Pronouncements - In July 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is currently evaluating the method of adoption and the impact of adopting ASU 2017-11 on its results of operations, cash flows and financial position.

2. FAIR VALUE

In accordance with Fair Value Measurements and Disclosures Topic of the FASB ASC 820, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.

	·	Level 1: Input prices quoted in an active market for identical financial assets or liabilities.
	·	Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets, and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.
	·	Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The Company issued warrants to purchase an aggregate of 82,500 common shares in a February 2013 public offering (the “February 2013 Public Offering Warrants”). On February 20, 2014, 27,500 of the February 2013 Public Offering Warrants expired. On May 20, 2016, 16,250 warrants were exercised. The remaining 38,750 warrants expired on February 20, 2018.

In August 2014, as part of an underwritten public offering, the Company issued 494,315 warrants to purchase common stock (the “August 2014 Warrants”). The August 2014 Warrants are listed on the NASDAQ Capital Market under the symbol “CLRBW,” however, there are certain periods where trading volume is low; therefore, they are classified as Level 2 within the hierarchy.

The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of March 31, 2018 and December 31, 2017:

	March 31, 2018
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
August 2014 Warrants	$	—	$	132,000	$	—	$	132,000
Total	$	—	$	132,000	$	—	$	132,000

	December 31, 2017
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	5,050	$	5,050
August 2014 Warrants		—		100,000		—		100,000
Total	$	—	$	100,000	$	5,050	$	105,050

In order to estimate the value of the February 2013 Public Offering Warrants considered to be derivative instruments, the Company uses a modified option-pricing model together with assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rates, volatility, the contractual term of the warrants, future financing requirements and dividend rates. The future financing estimates are based on the Company’s estimates of anticipated cash requirements over the term of the warrants as well as the frequency of required financings based on its assessment of its historical financing trends and anticipated future events. These warrants are classified within the Level 3 hierarchy because of the nature of the inputs and the valuation technique utilized.

The following table summarizes the modified option-pricing assumptions used:

	Three Months Ended March 31, 2018		Twelve Months Ended December 31, 2017
Volatility		N/A		76-118	%
Risk-free interest rate		N/A		1.03-1.39	%
Expected life (years)		N/A		0.14-0.89
Dividend		N/A		0	%

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.

	Three Months Ended March 31, 2018			Twelve Months Ended December 31, 2017
Beginning balance – Fair value	$	5,050		$	27,125
(Gain) on derivatives resulting from change in fair value or extinguishment		(5,050	)		(22,075	)
Ending balance – Fair value	$	—		$	5,050

To estimate the fair value of the August 2014 Warrants, the Company calculated the weighted average closing price for the trailing 10-day period with trades that ended on the balance sheet date.

3. STOCKHOLDERS’ EQUITY

Authorized Share Increase

At a special meeting held on September 12, 2017, the Company’s stockholders approved the ratification of the approval of the Certificate of Amendment to our Certificate of Incorporation to increase the number of authorized shares by 40,000,000 to 80,000,000 which was previously approved by the Company’s stockholders at our annual meeting of stockholders held on May 31, 2017.

October 2017 Registered Direct Offering

On October 12, 2017, the Company closed on a registered direct offering (the “October 2017 Registered Direct Offering”), priced at-the-market, of 1,954,388 shares of its common stock and 41.0412949 shares of its Series B Preferred Stock. The Series B Preferred Stock was offered at $100,000 per share and is immediately convertible into approximately 53,369 shares of common stock for a total of 2,190,330 shares upon conversion at a price of $1.87375 per share. The common stock was offered at $1.87375 per share. Gross offering proceeds to the Company were $7.76 million. In a concurrent private placement, the Company offered purchasers in the registered direct offering Series D warrants to purchase an aggregate of 3,108,538 shares of common stock, or 0.75 shares of common stock for each share of common stock purchased directly or issuable upon conversion of shares of preferred stock. The Series B Preferred Stock is non-voting, has no dividend rights (except to the extent dividends are also paid on common stock), liquidation preference, or other preferences over common stock. The Series D warrants are immediately exercisable at an exercise price of $1.78 per share and expire seven years from the closing. The Series D warrants, which are callable by the Company under certain circumstances, will not trade. Gross proceeds were approximately $7.8 million with net proceeds to the Company of approximately $7.1 million.

In order to account for the October 2017 Registered Direct Offering, the Company allocated the proceeds to the common stock, the Series B Preferred Stock and the Series D warrants on a relative fair value basis. Then using the effective conversion price of the Series B Preferred Stock, the Company determined that there was a beneficial conversion feature of $1,448,945.

On or prior to December 31, 2017, 23 shares of Series B Preferred Stock issued in the October 2017 Registered Direct Offering were converted into 1,227,485 shares of common stock. During the three months ended March 31, 2018, 6.5 shares of Series B Preferred Stock were converted into 346,898 shares of common stock. As of March 31, 2018 11.5 shares of Series B Preferred Stock remained outstanding which are convertible into 615,947 shares of common stock.

Common Stock Warrants

The following table summarizes information with regard to outstanding warrants to purchase common stock as of March 31, 2018.

Offering	Number of Shares Issuable Upon Exercise of Outstanding Warrants		Exercise Price		Expiration Date

October 2017 Series D Warrants		3,108,538	$	1.78	October 14, 2024
November 2016 Public Offering Series C		4,157,850	$	1.50	November 29, 2021
April 2016 Underwritten Registered Series A		3,626,942	$	3.04	April 20,2021
October 2015 Incremental Series A		300,006	$	2.13	October 20,2021
October 2015 Private Placement Series A		86,365	$	2.13	April 1, 2021
October 2015 Offering – Placement Agent		3,750	$	28.30	October 1, 2020
August 2014 Public Offering ⁽¹⁾		504,019	$	46.80	August 20, 2019
Total		11,787,470

(1)

These warrants have a certain type of cash settlement feature and they have been accounted for as derivative instruments as described in Note 1, with the exception of 9,704 warrants issued in August 2014.

4. STOCK-BASED COMPENSATION

Accounting for Stock-Based Compensation

During the three months ended March 31, 2018 there were no option grants issued. The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:

	Three Months Ended March 31,
	2018		2017

Employee and director stock option grants:
Research and development	$	34,127	$	16,648
General and administrative		139,311		149,026
Total stock-based compensation	$	173,438	$	165,674

Assumptions Used in Determining Fair Value

Valuation and amortization method. The fair value of each stock award is estimated on the grant date using the Black-Scholes option-pricing model. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. The estimated fair value of the non-employee options is amortized to expense over the period during which a non-employee is required to provide services for the award (usually the vesting period).

Volatility. The Company estimates volatility based on an average of (1) the Company’s historical volatility since its common stock has been publicly traded and (2) review of volatility estimates of publicly held drug development companies with similar market capitalizations.

Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.

Expected term. The expected term of stock options granted is based on an estimate of when options will be exercised in the future. The Company applied the simplified method of estimating the expected term of the options, as described in the SEC’s Staff Accounting Bulletins 107 and 110, as the historical experience is not indicative of the expected behavior in the future. The expected term, calculated under the simplified method, is applied to groups of stock options that have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. The Company applied the simplified method to non-employees who have a truncation of term based on termination of service and utilizes the contractual life of the stock options granted for those non-employee grants which do not have a truncation of service.

Forfeitures. The Company records stock-based compensation expense only for those awards that are expected to vest. A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. An annual forfeiture rate of 2% was applied to all unvested options for employees and directors, respectively, for the three months ended March 31, 2018 and for the year ended December 31, 2017. Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.

There were no stock option grants during the three months ended March 31, 2018.

Stock Option Activity

A summary of stock option activity is as follows:

	Number of Shares Issuable Upon Exercise of Outstanding Options			Weighted Average Exercise Price		Weighted Average Remaining Contracted Term in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2017		531,729		$	6.55
Granted		—		$	—
Expired		(4,350	)	$	48.57
Forfeited		(17,987	)	$	1.89
Outstanding at March 31, 2018		509,392		$	6.36

Exercisable, March 31, 2018		278,499		$	8.40		7.75	$	—
Unvested, March 31, 2018		230,893		$	3.89		8.48	$	—

The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the estimated per-share fair value of common stock at the end of the respective period and the exercise price of the underlying options. There have been no option exercises to date. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.

As of March 31, 2018, there was approximately $1,023,289 of total unrecognized compensation cost related to unvested stock-based compensation arrangements. Of this total amount, the Company expects to recognize approximately $489,116, $462,703, and $71,470 during 2018, 2019, and 2020, respectively. The Company’s expense estimates are based upon the expectation that all unvested options will vest in the future, less the forfeiture rate discussed above. The weighted-average grant-date fair value of vested and unvested options outstanding at March 31, 2018 was $6.67 and $3.18, respectively.

Restricted Stock Grants. During 2017, the Company granted 480,000 shares of restricted common stock with a weighted average grant date fair value of $2.10. The shares vest annually over a three year period. As of December 31, 2017 380,000 shares of restricted common stock were outstanding. There were no restricted stock grants issued during the three months ended March 31, 2018. A summary of restricted stock activity is as follows:

Outstanding at December 31, 2017	380,000
Granted	—
Vested	(93,332	)
Outstanding at March 31, 2018	286,668

5. NOTES PAYABLE

During the quarter ended March 31, 2017, the two loans with initial principal amounts totaling $450,000 from the Wisconsin Economic Development Corporation, dated September 15, 2010, were paid in full.

6. INCOME TAXES

The Company accounts for income taxes in accordance with the liability method of accounting. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax basis of assets and liabilities, and net operating loss carryforwards, (NOLs) using the enacted tax rates. Deferred income tax expense or benefit is based on changes in the asset or liability from period to period. The Company did not record a provision or benefit for federal, state or foreign income taxes for the three months ended March 31, 2018 or 2017 because the Company has experienced losses on a tax basis since inception. Because of the limited operating history, continuing losses and uncertainty associated with the utilization of the NOLs in the future, management has provided a full allowance against the value of its gross deferred tax assets.

The Company also accounts for the uncertainty in income taxes related to the recognition and measurement of a tax position taken or expected to be taken in an income tax return. The Company follows the applicable accounting guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition related to the uncertainty in income tax positions. No uncertain tax positions have been identified.

7. NET LOSS PER SHARE

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share for the three months ended March 31, 2018 is computed by dividing net income by the sum of the weighted average number of shares of common stock and the dilutive potential common stock equivalents then outstanding. Potential common stock equivalents consist of stock options, non-vested restricted stock and warrants. Since there is a net loss attributable to common stockholders for the three months ended March 31, 2018, the inclusion of common stock equivalents in the computation for that period would be antidilutive.

The following potentially dilutive securities have been excluded from the computation of diluted net income (loss) per share since their inclusion would be antidilutive:

	Three Months Ended March 31,
	2018		2017
Warrants		11,787,470		8,760,446
Preferred shares as converted into common stock		615,947		—
Stock options		509,392		508,733
Non-vested restricted stock		286,668		—
Total potentially dilutive shares		13,199,477		9,269,179

8. COMMITMENTS AND CONTINGENCIES

The Company is involved in legal matters and disputes in the ordinary course of business. We do not anticipate that the outcome of such matters and disputes will materially affect the Company’s financial statements.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Cellectar Biosciences, Inc. (the “Company”) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company’s core objective is to leverage its proprietary phospholipid drug conjugate^TM (PDCs^TM) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC^TM platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and the Company plans to develop PDCs independently and through research and development collaborations.

Our lead PDC candidate, CLR 131, provides targeted delivery of the cytotoxic (cell-killing) radioisotope iodine 131. CLR 131 is in a Phase 1 clinical study for relapsed or refractory (R/R) multiple myeloma (MM) and a Phase 2 clinical study in R/R MM and a range of other B-cell malignancies. In the second half of 2018, the company plans to initiate a Phase 1 study for pediatric solid tumors and lymphomas and a second Phase 1 study of CLR 131 in combination with external beam radiation for head and neck cancer. The company’s pipeline also includes two preclinical PDC chemotherapeutic programs, CLR 1700 and 1900. CLR 1700 possess a Burton’s tyrosine kinase inhibitor (BTK) payload and is targeted for development in hematologic cancers and CLR 1900 is being developed for solid tumors with a payload that inhibits mitosis (cell division) which is a validated pathway for cell apoptosis.

Our PDC platform provides selective delivery of a diverse range of oncologic payloads to cancerous cells, whether a hematologic cancer or solid tumor, the primary tumor, or a metastatic tumor and cancer stem cells. Our PDC platform takes advantage of a metabolic pathway utilized by all tumor cell types in all stages of the tumor “cycle.” This allows the PDC molecules to gain access to the intracellular compartment of the tumor cells and for the PDCs to continue to accumulate over time, which enhances drug efficacy. The PDC platform’s mechanism of entry does not rely upon specific cell surface epitopes or antigens as are required by other targeted delivery platforms. Specific cell surface epitopes are limited in number on the cell surface, undergo internalization and cycling upon binding and are not present on all tumor cells of a particular cancer type. This means a subpopulation of tumor cells will always remain. In addition to the benefits provided by the mechanism of entry, PDCs offer the potential advantage of having the ability to be conjugated to molecules in numerous ways, thereby increasing the types of molecules selectively delivered via the PDC.

We employ a drug discovery and development approach that allows us to efficiently design, research and advance drug candidates. Our iterative process allows us to rapidly and systematically produce multiple generations of incrementally improved targeted drug candidates.

Clinical Pipeline

CLR 131 is a small-molecule, cancer-targeting radiotherapeutic PDC designed to deliver cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. CLR 131 is our lead therapeutic PDC product candidate and is currently being evaluated in both Phase 2 and Phase 1 clinical studies. The Investigational New Drug (IND) application was accepted by the U.S. Food and Drug Administration (FDA) in March 2014. In December 2014, the FDA granted orphan drug designation for CLR 131 for the treatment of multiple myeloma (MM) and the Phase 1 study was initiated in April 2015. This clinical study is a standard three-by-three dose escalation safety study in patients with relapse or refractory multiple myeloma (R/RMM). Multiple myeloma is an incurable cancer of the plasma cells and is the second most common form of hematologic cancers. This cancer type was selected for clinical, regulatory and commercial rationales, including multiple myeloma’s highly radiosensitive nature, and continued unmet medical need in the relapse/refractory setting and has been determined to be a rare disease by the FDA based upon the current definition within the Orphan Drug Act. The primary goal of the Phase 1 study is to assess the compound’s safety and tolerability in patients with relapsed or refractory multiple myeloma. Secondary objectives include the establishment of a recommended Phase 2 dose, both with and without dexamethasone, as well as an evaluation of therapeutic activity by assessing surrogate efficacy markers which include M protein, Free Light Chain (FLC), Progression Free Survival (PFS) and Overall Survival (OS). The FDA granted orphan drug designation for CLR 131 for the treatment of neuroblastoma in March 2018 and rhabdomyosarcoma in May 2018. In April 2018, the FDA granted a rare pediatric disease designation (RPDD) for CLR 131 also for the treatment of neuroblastoma. The FDA previously accepted our IND application for a Phase 1 open-label, dose-escalating study to evaluate the safety and tolerability of a single intravenous administration of CLR 131 in up to 30 children and adolescents with cancers including neuroblastoma, sarcomas, lymphomas (including Hodgkin’s lymphoma) and malignant brain tumors. We expect to initiate this study during the second half of 2018.

Phase 2 Study in Patients with R/R select B-Cell Malignancies

In July 2016, we were awarded a $2,000,000 National Cancer Institute Fast-Track Small Business Innovation Research (SBIR) grant to further advance the clinical development of CLR 131. The funds are supporting the Phase 2 study initiated in March 2017 to define the clinical benefits of CLR 131 in R/RMM and other niche hematologic malignancies with high unmet clinical need. These niche hematologic malignancies include Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, and Diffuse Large B-Cell Lymphoma. The study will be conducted in approximately 10 top U.S. cancer centers in patients with orphan-designated relapse or refractory hematologic cancers. The study's primary endpoint is clinical benefit response (CBR), with additional endpoints of progression free survival PFS, median OS and other markers of efficacy following a single 25.0 mCi/m² dose of CLR 131, with the option for a second 25.0 mCi/m² dose approximately 75-180 days later. On January 29, 2018 the fourth cohort was initiated and patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) cancers began enrolling in the study.

Phase 1 Study in Patients with R/R Multiple Myeloma

CLR 131 in combination with dexamethasone is currently under investigation in a Phase 1 trial in adult patients with relapsed/refractory MM following treatment with both a proteasome inhibitor and an immunomodulatory agent. All patients have been heavily pretreated. To date, 4 dose cohorts have been examined: 12.5 mCi/m², 18.75 mCi/m², 25 mCi/m², and 31.25 mCi/m², all in combination with 40 mg dexamethasone weekly. Eighteen patients have been dosed to date and an independent Data Monitoring Committee has confirmed all four dose levels safe and tolerable. Of the 5 patients in the first cohort, 4 achieved SD (1 patient progressed at Day 15 after administration and was taken off the study). Of the five patients have been admitted to the second cohort, 4 achieved SD (1 patient progressed at Day 41 after administration and was taken off study). Four patients were enrolled to the third cohort and all achieved stable disease. In September 2017, Cohort 4 results were announced and these results showed that a single 30 minute infusion of 31.25mCi/m² of CLR 131 was safe and well tolerated by the three patients in the cohort. Additionally, all three patients experienced clinical benefit with one patient achieving a partial response (PR). We are monitoring response rates via surrogate markers of efficacy including M protein and free light chain FLC. The International Myeloma Working Group (IMWG) defines a PR as a greater than or equal to 50 percent decrease in FLC levels (for patients in whom M protein is unmeasurable) or 50 percent decrease in M protein. The patient experiencing a PR had an 82 percent reduction in FLC. This patient did not produce M protein, received seven prior lines of treatment including radiation, stem cell transplantation and multiple triple combination treatments including one with daratumumab that was not tolerated. One patient experiencing stable disease attained a 44 percent reduction in M protein. We have recently converted the Phase 1a clinical data (single CLR 131 dose) to pooled data for presentation of the total performance of the results to date as the pooled data is more likely to be reflective of larger Phase 2/3 clinical studies. This is beneficial as it is a compilation of all the data and results in an N of 15, which gives the data more weight and a sense of maturity compared to reporting on individual cohorts with an N of 3-4 in each. As of February 2018, the preliminary pooled overall survival data from the first four cohorts was 15.0 months. This preliminary data point is a compilation of all four cohorts that were enrolled at different times over the entirety of the study and will not be considered final until the median survival is met for all patients.

Based on the safety observed to date as well as various efficacy signals, including reductions in m-protein and free light chain, the fact that we have not yet reached median overall survival at this time, we modified the protocol to begin a second part and a cohort 5, the main objective of which is to determine an optimal dose-range for CLR 131. Cohort 5 is actively enrolling and should complete by the end of the second quarter. In this cohort, we split the 31.25 mCi/m² dose into two 30-minute infusions of 15.625 mCi/m² doses given approximately one week apart.

Phase 1 Study in R/R Pediatric Patients with select Solid tumors, Lymphomas and Malignant Brain Tumors.

On December 14, 2017, we filed an IND application with the Division of Oncology at the FDA for a proposed Phase 1 study of CLR 131 in children and adolescents with select rare and orphan designated cancers. The Phase 1 clinical trial of CLR 131 is an open-label, sequential-group, dose-escalation study to evaluate the safety and tolerability of a single intravenous administration of CLR 131 in up to 30 children and adolescents with cancers including neuroblastoma, sarcomas, lymphomas (including Hodgkin's lymphoma) and malignant brain tumors. Secondary objectives of the study are to identify the recommended Phase 2 dose of CLR 131 and to determine preliminary antitumor activity (treatment response) of CLR 131 in children and adolescents. The FDA granted orphan drug designation for CLR 131 for the treatment of neuroblastoma in March 2018 and rhabdomyosarcoma in May 2018.. We expect to initiate the Phase 1 study during the second half of 2018.

The study will be initiated with the pediatric oncologists and Nuclear Medicine/Radiology Group at the University of Wisconsin Carbone Cancer Center (UWCCC). Investigators at The University of Wisconsin have demonstrated uptake of CLR 131 and other fluorescently and isotopically tagged PDCs across a wide range of childhood solid cancer cell lines including, Ewing sarcoma, rhabdomyosarcoma, pediatric brain tumors such as high-grade gliomas, medulloblastoma and atypical teratoid rhabdoid tumor. In subsequent testing in mouse xenograft models of neuroblastoma, Ewing sarcoma, rhabdomyosarcoma and osteosarcoma, CLR 131 provided significant benefits on tumor growth rates and survival.

Phase 1 Study in R/R Head and Neck Cancer

In August 2016, the UWCCC was awarded a five year Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute to improve treatments and outcomes for head and neck cancer (HNC) patients. HNC is the sixth most common cancer across the world with approximately 56,000 new patients diagnosed every year in the United States. As a key component of this grant, the UWCCC researchers will test CLR 131 in various animal HNC models as well as initiating the first human clinical trial combining CLR 131 and external beam radiation in patients with recurrent HNC. The UWCCC is currently anticipated to initiate this clinical trial in 2H 2018.

Pre-Clinical Pipeline

•

CLR 1700 Series is an internally developed PDC program leveraging a payload which inhibits Burton’s tyrosine kinase (BTK) and is designed to treat a broad range of hematologic cancers. The payload provides further specificity by targeting a pathway within hematologic cancers that is significantly upregulated in comparison to normal tissue. We believe that this additional level of targeting will allow us to provide a new drug candidate that has the ability to significantly improve patient outcomes. Leveraging our iterative discovery and screening process, we have been able to accelerate the development of this program.

•

CLR 1800 Series is a collaborative PDC program with Pierre Fabre that we entered into in December 2015 and extended in October 2017. Pierre Fabre is the third largest French pharmaceutical company with an extensive oncology research and development infrastructure. The objective of the research collaboration is to co-design a library of PDCs employing Pierre Fabre’s chemotherapeutics in combination with our proprietary cancer-targeting delivery vehicle. The newly developed PDCs may provide enhanced therapeutic indices to otherwise highly potent, non-targeted payloads through the targeted delivery to cancer cells provided by our cancer-targeting delivery vehicle. Significant progress has been achieved and the program continues to rapidly advance with a number of PDC molecules showing enhanced pharmacologic behavior over the parent compound alone.

•

CLR 1900 Series is an internally developed proprietary PDC program leveraging a novel small molecule cytotoxic compound as the payload. The payload inhibits mitosis (cell division) and targets a key pathway required to inhibit rapidly dividing cells that results in apoptosis. We believe that this program could produce a product candidate targeted to select solid tumors. Currently, the program is in early preclinical development.

•

CLR 2000 Series is a collaborative PDC program with Avicenna Oncology, or Avicenna, that we entered into in July 2017. Avicenna is a leading developer of antibody drug conjugates (ADCs). The objective of the research collaboration is to design and develop a series of PDCs utilizing Avicenna’s proprietary cytotoxic payload. Although Avicenna is a leading developer of ADCs, this collaboration was sought as a means to overcome many of the challenges associated with ADCs, including those associated with the targeting of specific cell surface epitopes.

•

CLR 2100 and 2200 Series are collaborative PDC programs with Onconova Therapeutics, Inc., or Onconova, that we entered into in September 2017. Onconova is a biotechnology company specializing in the discovery and development of novel small molecule cancer therapies. The collaboration is structured such that we will design and develop a series of PDCs utilizing different small molecules that Onconova was developing as payloads with the intent to show improved targeting and specificity to the tumor. At least one of the molecules was taken into Phase 1 clinical trials previously by Onconova. We would own all new intellectual property associated with the design of the new PDCs and both companies will have the option to advance compounds.

We believe our PDC platform has potential to provide targeted delivery of a diverse range of oncologic payloads, as exemplified by the product candidates listed above, that may result in improvements upon current standard of care (SOC) for the treatment of a broad range of human cancers.

Results of Operations

Research and development expense. Research and development expense consists of costs incurred in identifying, developing and testing, and manufacturing product candidates, which primarily include salaries and related expenses for personnel, costs of our research and manufacturing facility, cost of manufacturing materials and contract manufacturing fees paid to contract research organizations, fees paid to medical institutions for clinical trials, and costs to secure intellectual property. The Company analyzes its research and development expenses based on four categories as follows: clinical projects, preclinical projects, chemistry and manufacturing costs, and general fixed and overhead costs that are not allocated to the functional project costs, including personnel costs, facility costs, related overhead costs and patent costs.

General and administrative expense. General and administrative expense consists primarily of salaries and other related costs for personnel in executive, finance and administrative functions. Other costs include insurance, costs for public company activities, investor relations, directors’ fees and professional fees for legal and accounting services.

Three Months Ended March 31, 2018 and 2017

Research and Development. Research and development expense for the three months ended March 31, 2018 was approximately $2,124,000 (composed of $524,000 in clinical project costs, $574,000 in pre-clinical project costs, $480,000 of manufacturing and related costs and $546,000 in general unallocated research and development costs) compared to approximately $1,857,000 (composed of $501,000 in clinical project costs, $430,000 of manufacturing and related costs, $33,000 in pre-clinical project costs, and $893,000 in general unallocated research and development costs) for the three months ended March 31, 2017. The increase of $267,000 or 14% was primarily the result of an increase of approximately $541,000 in pre-clinical costs offset by a decrease of $210,000 in purchased services resulting from NCI reimbursements and a $71,000 decrease in depreciation expense.

General and Administrative. General and administrative expense for the three months ended March 31, 2018 was approximately $1,329,000 compared to approximately $955,000 in the three months ended March 31, 2017. The overall increase of approximately $374,000, or 39% was primarily attributable to an approximately $298,000 increase in purchased services, primarily consulting, legal and marketing fees. In connection with the decision to outsource our manufacturing, we incurred approximately $81,000 of one time personnel related costs in the first quarter ended March 31, 2018. Our headcount decreased from 15 at December 31, 2017 to 10 at March 31, 2018.

Loss on Derivative Warrants. We recorded a loss on derivative warrants of approximately $26,950 in the three months ended March 31, 2018, as compared to a loss of approximately $82,475 in the three months ended March 31, 2017. These amounts represent the change in fair value (resulting primarily from changes in the Company’s stock price as well as a reduction in term), during the respective periods, of outstanding warrants which are classified as liabilities because they contain a certain type of cash settlement feature, “down-round” anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise prices of the warrants. The fluctuations we experienced in historical periods have been substantially reduced as a result of the renegotiation or extinguishment of a significant portion of the liability-classified warrants.

Interest income, net. Interest income, net, for the three months ended March 31, 2018 was approximately $5,000, as compared to approximately $3,000 for the three months ended March 31, 2017. The increase resulted from the interest earned on the Company’s cash equivalents.

Liquidity and Capital Resources

As of March 31, 2018, we had cash and cash equivalents of approximately $6,820,000 compared to $10,006,000 as of December 31, 2017. This decrease was largely attributable to our cash used in operating activities of approximately $3,184,000 during the three months ended March 31, 2018. Net cash used in operating activities during the three months ended March 31, 2017 was approximately $3,184,000.

Our cash requirements have historically been for our research and development activities, finance and administrative costs, capital expenditures and overall working capital. We have experienced negative operating cash flows since inception and have funded our operations primarily from sales of common stock and other securities. As of March 31, 2018, we had an accumulated deficit of approximately $87,825,000.

We believe our March 31, 2018 cash balance of approximately $6,820,000 is adequate to fund operations into early first quarter of 2019. Our ability to execute our operating plan beyond early first quarter of 2019 depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. We plan to actively pursue all available financing alternatives; however, there can be no assurance that we will obtain the necessary funding. If we are unsuccessful in raising additional capital, we may need to reduce activities, curtail or cease operations. Other than the uncertainties regarding our ability to obtain additional funding, there are currently no known trends, demands, commitments, events or uncertainties that are likely to materially affect our liquidity.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures. Based on our management’s evaluation (with the participation of our principal executive officer and principal financial officer), as of March 31, 2018, our management has concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

Changes in internal control over financial reporting. There have not been any significant changes in the Company’s internal control of financial reporting.

The Chief Executive Officer and the Audit Committee perform significant roles in ensuring the accuracy and completeness of our financial reporting and the effectiveness of our disclosure controls and procedures. We have not identified any changes that occurred during the Company’s fiscal quarter ended March 31, 2018 that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Important Considerations. Any system of controls, however well designed and operated, can provide only reasonable, and not absolute assurance that the objectives of the system are met. In addition, the design of any control system is based in part on certain assumptions about the likelihood of future events. The effectiveness of our disclosure controls and procedures is subject to various inherent limitations, including cost limitations, judgments used in decision making, assumptions about the likelihood of future events, the soundness of our systems, the possibility of human error, and the risk of fraud. Because of these and other inherent limitations of control systems, there can be no assurance that any system of disclosure controls and procedures will be successful in achieving its stated goals, including but not limited to preventing all errors or fraud or in making all material information known in a timely manner to the appropriate levels of management, under all potential future conditions, regardless of how remote.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

None.

Item 1A.

Risk Factors

We will require additional capital in order to continue our operations, and may have difficulty raising additional capital.

We expect that we will continue to generate significant operating losses for the foreseeable future. At March 31, 2018, our consolidated cash balance was approximately $6.8 million. We believe our cash balance at March 31, 2018, is adequate to fund operations at budgeted levels into the first quarter of 2019. We will require additional funds to conduct research and development, establish and conduct clinical and preclinical trials, establish commercial-scale manufacturing arrangements and provide for the marketing and distribution of our products. Our ability to execute our operating plan depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. We plan to actively pursue financing alternatives. However, there can be no assurance that we will obtain the necessary funding in the amounts we seek or that it will be available on a timely basis or upon terms acceptable to us. If we obtain capital by issuing debt or preferred stock, the holders of such securities would likely obtain rights that are superior to those of holders of our common stock.

Our capital requirements and our ability to meet them depend on many factors, including:

	·	the number of potential products and technologies in development;
	·	continued progress and cost of our research and development programs;
	·	progress with preclinical studies and clinical trials;
	·	the time and costs involved in obtaining regulatory clearance;
	·	costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims;
	·	costs of developing sales, marketing and distribution channels and our ability to sell our drugs;
	·	costs involved in establishing manufacturing capabilities for clinical trial and commercial quantities of our drugs;
	·	competing technological and market developments;
	·	market acceptance of our products;
	·	costs for recruiting and retaining management, employees and consultants;
	·	costs for educating physicians regarding the application and use of our products;
	·	whether we are able to maintain our listing on a national exchange;
	·	uncertainty and economic instability resulting from terrorist acts and other acts of violence or war; and
	·	the condition of capital markets and the economy generally, both in the U.S. and globally.

We may consume available resources more rapidly than currently anticipated, resulting in the need for additional funding sooner than expected. We may seek to raise any necessary additional funds through the issuance of warrants, equity or debt financings or executing collaborative arrangements with corporate partners or other sources, which may be dilutive to existing stockholders or have a material effect on our current or future business prospects. In addition, in the event that additional funds are obtained through arrangements with collaborative partners or other sources, we may have to relinquish economic and/or proprietary rights to some of our technologies or products under development that we would otherwise seek to develop or commercialize by ourselves. If we cannot secure adequate financing when needed, we may be required to delay, scale back or eliminate one or more of our research and development programs or to enter into license or other arrangements with third parties to commercialize products or technologies that we would otherwise seek to develop ourselves and commercialize ourselves. In such an event, our business, prospects, financial condition, and results of operations may be adversely affected.

We will require additional funds to conduct research and development, establish and conduct preclinical and clinical trials, establish commercial-scale manufacturing arrangements and provide for the marketing and distribution of our products. Our ability to execute our operating plan depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise.

We have incurred net losses and negative cash flows since inception. We currently have no product revenues, and may not succeed in developing or commercializing any products that will generate product or licensing revenues. We do not expect to have any products on the market for several years. Our primary activity to date has been research and development and conducting clinical trials. Development of our product candidates requires a process of preclinical and clinical testing, during which our product candidates could fail. We may not be able to enter into agreements with one or more companies experienced in the manufacturing and marketing of therapeutic drugs and, to the extent that we are unable to do so, we may not be able to market our product candidates. Whether we achieve profitability or not will depend on our success in developing, manufacturing, and marketing our product candidates. We have experienced net losses and negative cash flows from operating activities since inception and we expect such losses and negative cash flows to continue for the foreseeable future. As of March 31, 2018, we had a stockholders’ equity of approximately $7,452,000. The operating loss for the three months ended March 31, 2018 was approximately $3,454,000, and we may never achieve profitability.

Item 6.

Exhibits

			Incorporation by Reference
Exhibit No.	Description	Filed with this Form 10-Q	Form	Filing Date	Exhibit No.

10.1	Offer Letter between the Company and Brian Posner dated April 1, 2018		8-K	April 4, 2018	10.1

31.1	Certification of chief executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

31.2	Certification of chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

32.1	Certification of chief executive officer and chief financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

101	Interactive Data Files	X

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CELLECTAR BIOSCIENCES, INC.

Date: May 11, 2018	By:	/s/ James V. Caruso
		James V. Caruso
		President and Chief Executive Officer

EX-31.1 2 tv492649_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

I, JAMES V. CARUSO, certify that:

I have reviewed this quarterly report on Form 10-Q of Cellectar Biosciences, Inc., a Delaware Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially effect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2018

/s/ James V. Caruso
James V. Caruso
President and Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 tv492649_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

I, BRIAN M. POSNER, certify that:

I have reviewed this quarterly report on Form 10-Q of Cellectar Biosciences, Inc., a Delaware Corporation;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2018

/s/ Brian M. Posner
Brian M. Posner
Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 4 tv492649_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. § 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Cellectar Biosciences, Inc. (the “Company”) for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, James V. Caruso, President and Chief Executive Officer of the Company, and Brian M. Posner, Vice President, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to our knowledge, that:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ James V. Caruso
James V. Caruso
President and Chief Executive Officer (Principal Executive Officer)

Date: May 11, 2018

/s/ Brian M. Posner
Brian M. Posner
Chief Financial Officer (Principal Financial and Accounting Officer)

Date: May 11, 2018

EX-101.INS 5 clrb-20180331.xml XBRL INSTANCE DOCUMENT 0001279704 2017-01-01 2017-03-31 0001279704 2018-01-01 2018-03-31 0001279704 2018-03-31 0001279704 2018-05-07 0001279704 2017-09-12 0001279704 2017-12-31 0001279704 2016-12-31 0001279704 2017-03-31 0001279704 clrb:February2013PublicOfferingWarrantsMember 2013-02-28 0001279704 clrb:February2013PublicOfferingWarrantsMember 2014-02-01 2014-02-20 0001279704 clrb:February2013PublicOfferingWarrantsMember 2016-05-01 2016-05-20 0001279704 clrb:February2013PublicOfferingWarrantsMember us-gaap:FairValueInputsLevel3Member 2016-05-20 0001279704 clrb:August2014PublicOfferingWarrantsMember 2014-08-31 0001279704 us-gaap:FairValueInputsLevel1Member 2018-03-31 0001279704 us-gaap:FairValueInputsLevel2Member 2018-03-31 0001279704 us-gaap:FairValueInputsLevel3Member 2018-03-31 0001279704 us-gaap:FairValueInputsLevel1Member clrb:WarrantTwoMember 2018-03-31 0001279704 us-gaap:FairValueInputsLevel2Member clrb:WarrantTwoMember 2018-03-31 0001279704 us-gaap:FairValueInputsLevel3Member clrb:WarrantTwoMember 2018-03-31 0001279704 clrb:WarrantTwoMember 2018-03-31 0001279704 us-gaap:FairValueInputsLevel1Member clrb:February2013PublicOfferingWarrantsMember 2017-12-31 0001279704 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001279704 us-gaap:FairValueInputsLevel2Member clrb:February2013PublicOfferingWarrantsMember 2017-12-31 0001279704 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001279704 us-gaap:FairValueInputsLevel3Member clrb:February2013PublicOfferingWarrantsMember 2017-12-31 0001279704 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001279704 clrb:February2013PublicOfferingWarrantsMember 2017-12-31 0001279704 us-gaap:FairValueInputsLevel1Member clrb:WarrantTwoMember 2017-12-31 0001279704 us-gaap:FairValueInputsLevel2Member clrb:WarrantTwoMember 2017-12-31 0001279704 us-gaap:FairValueInputsLevel3Member clrb:WarrantTwoMember 2017-12-31 0001279704 clrb:WarrantTwoMember 2017-12-31 0001279704 us-gaap:FairValueInputsLevel3Member 2016-12-31 0001279704 us-gaap:FairValueInputsLevel3Member 2018-01-01 2018-03-31 0001279704 us-gaap:FairValueInputsLevel3Member 2017-01-01 2017-12-31 0001279704 clrb:November2016PublicOfferingSeriesCMember 2018-03-31 0001279704 clrb:April2016UnderwrittenRegisteredSeriesMember 2018-03-31 0001279704 clrb:October2015IncrementalSeriesMember 2018-03-31 0001279704 clrb:October2015PrivatePlacementSeriesMember 2018-03-31 0001279704 clrb:October2015OfferingPlacementAgentMember 2018-03-31 0001279704 clrb:August2014PublicOfferingMember 2018-03-31 0001279704 clrb:November2016PublicOfferingSeriesCMember 2018-01-01 2018-03-31 0001279704 clrb:April2016UnderwrittenRegisteredSeriesMember 2018-01-01 2018-03-31 0001279704 clrb:October2015IncrementalSeriesMember 2018-01-01 2018-03-31 0001279704 clrb:October2015PrivatePlacementSeriesMember 2018-01-01 2018-03-31 0001279704 clrb:October2015OfferingPlacementAgentMember 2018-01-01 2018-03-31 0001279704 clrb:August2014PublicOfferingMember 2018-01-01 2018-03-31 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-03-31 0001279704 us-gaap:SecuredDebtMember 2017-03-31 0001279704 us-gaap:SeriesBPreferredStockMember 2018-03-31 0001279704 us-gaap:SeriesBPreferredStockMember 2017-12-31 0001279704 clrb:TwoThousandThirteenWarrantsMember 2018-01-01 2018-03-31 0001279704 us-gaap:MinimumMember clrb:TwoThousandThirteenWarrantsMember 2017-01-01 2017-12-31 0001279704 us-gaap:MaximumMember clrb:TwoThousandThirteenWarrantsMember 2017-01-01 2017-12-31 0001279704 clrb:TwoThousandThirteenWarrantsMember 2017-01-01 2017-12-31 0001279704 clrb:October2017SeriesDWarrantsMember 2018-03-31 0001279704 clrb:October2017SeriesDWarrantsMember 2018-01-01 2018-03-31 0001279704 us-gaap:CommonStockMember clrb:October2017RegisteredPublicOfferingMember 2017-10-01 2017-10-12 0001279704 clrb:October2017RegisteredPublicOfferingMember us-gaap:SeriesBPreferredStockMember 2017-10-01 2017-10-12 0001279704 clrb:October2017RegisteredPublicOfferingMember us-gaap:SeriesBPreferredStockMember 2017-10-12 0001279704 clrb:October2017RegisteredPublicOfferingMember us-gaap:CommonStockMember 2017-10-12 0001279704 clrb:October2017RegisteredPublicOfferingMember 2017-10-01 2017-10-12 0001279704 clrb:October2017RegisteredPublicOfferingMember clrb:SeriesDWarrantsMember 2017-10-12 0001279704 clrb:October2017RegisteredPublicOfferingMember clrb:SeriesDWarrantsMember 2017-10-01 2017-10-12 0001279704 us-gaap:SeriesBPreferredStockMember 2018-01-01 2018-03-31 0001279704 us-gaap:SeriesBPreferredStockMember 2017-01-01 2017-12-31 0001279704 clrb:August2014UnderwrittenOfferingMember 2014-08-31 0001279704 us-gaap:WarrantMember us-gaap:ConvertibleDebtMember 2018-01-01 2018-03-31 0001279704 us-gaap:StockOptionMember us-gaap:ConvertibleDebtMember 2018-01-01 2018-03-31 0001279704 us-gaap:WarrantMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-03-31 0001279704 clrb:PreferredSharesAsConvertedIntoCommonStockMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-03-31 0001279704 us-gaap:StockOptionMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-03-31 0001279704 us-gaap:RestrictedStockMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-03-31 0001279704 us-gaap:ConvertibleDebtMember 2017-01-01 2017-03-31 0001279704 clrb:PreferredSharesAsConvertedIntoCommonStockMember us-gaap:ConvertibleDebtMember 2018-01-01 2018-03-31 0001279704 us-gaap:RestrictedStockMember us-gaap:ConvertibleDebtMember 2018-01-01 2018-03-31 0001279704 us-gaap:ConvertibleDebtMember 2018-01-01 2018-03-31 0001279704 us-gaap:RestrictedStockMember 2017-12-31 0001279704 us-gaap:RestrictedStockMember 2018-01-01 2018-03-31 0001279704 us-gaap:RestrictedStockMember 2018-03-31 0001279704 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2018-03-31 2018 Q1 Cellectar Biosciences, Inc. 0001279704 --12-31 Smaller Reporting Company CLRB 17388344

6820163

10006421

770012

877996

7645175

10939417

228836

244713

1675462

11872

9561345

12871464

1883783

1867758

132000

105050

3119

3036

2107866

2114788

1402

2213

1402

2213

2109268

2117001

637017

995782

171

167

94640028

94107830

-87825139

-84349316

7452077

10754463

9561345

12871464

55000

1856880

955356

2812236

-2812236

-82475

3387

-2891324

-79088

2124060

1329467

3453527

-3453527

-26950

4654

-3475823

-22296

17301

86911

173438

165674

16025

-230341

-107984

199616

-3184105

-2987437

1425

66301

-1425

-66301

728

655

-728

2847513

-3186258

-206225

364

49980

1216

2934759

86591

82500

27500

16250

38750

494315

132000

100000

5050

100000

5050 27125

-5050

-22075

11787470

4157850

3626942

300006

86365

3750

504019

1.5

3.04

2.13

28.3

46.8

2021-11-29 2021-04-20 2021-10-20 2021-04-01 2020-10-01 2019-08-20

34127

139311

16648

149026

230893 3.89 0 P8Y5M23D

531729

17987

6.55

1.89

509392

6.36

4350

48.57

1023289

489116

6.67

3.18

450000

88964

138944

0.00001

7000

0.00001

80000000

16661446

17101676

11.5

-0.21

-0.24

16808189

12010284

494315

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>2. FAIR VALUE</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In accordance with Fair Value Measurements and Disclosures Topic of the FASB ASC 820, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1%"> <div> </div> </td> <td style="WIDTH: 3%"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Symbol"> ⋅</font></div> </td> <td style="WIDTH: 96%"> <div><font style="FONT-SIZE: 10pt">Level 1: Input prices quoted in an active market for identical financial assets or liabilities.</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div> </div> </td> <td> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Symbol"> ⋅</font></div> </td> <td> <div><font style="FONT-SIZE: 10pt">Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets, and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div> </div> </td> <td> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Symbol"> ⋅</font></div> </td> <td> <div><font style="FONT-SIZE: 10pt">Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company issued warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 82,500</font> common shares in a February 2013 public offering (the “February 2013 Public Offering Warrants”). On February 20, 2014, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 27,500</font> of the February 2013 Public Offering Warrants expired. On May 20, 2016, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 16,250</font> warrants were exercised. The remaining <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 38,750</font> warrants expired on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">February 20, 2018</font>.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In August 2014, as part of an underwritten public offering, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 494,315</font> warrants to purchase common stock (the “August 2014 Warrants”). The August 2014 Warrants are listed on the NASDAQ Capital Market under the symbol “CLRBW,” however, there are certain periods where trading volume is low; therefore, they are classified as Level 2 within the hierarchy.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of March 31, 2018 and December 31, 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div style="CLEAR:both;CLEAR: both">March 31, 2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both">Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">August 2014 Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">132,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">132,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">132,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">132,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div style="CLEAR:both;CLEAR: both"> December 31, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both">Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">February 2013 Public Offering Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">August 2014 Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">105,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In order to estimate the value of the February 2013 Public Offering Warrants considered to be derivative instruments, the Company uses a modified option-pricing model together with assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rates, volatility, the contractual term of the warrants, future financing requirements and dividend rates. The future financing estimates are based on the Company’s estimates of anticipated cash requirements over the term of the warrants as well as the frequency of required financings based on its assessment of its historical financing trends and anticipated future events. These warrants are classified within the Level 3 hierarchy because of the nature of the inputs and the valuation technique utilized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the modified option-pricing assumptions used:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Three Months <br/> Ended  <br/> March 31, <br/> 2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Twelve Months <br/> Ended <br/> December 31, <br/> 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">76-118</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.03-1.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.14-0.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Three Months<br/> Ended <br/> March 31,<br/> 2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Twelve Months<br/> Ended <br/> December 31,<br/> 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Beginning balance  Fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">27,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">(Gain) on derivatives resulting from change in fair value or extinguishment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(5,050)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(22,075)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Ending balance  Fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> To estimate the fair value of the August 2014 Warrants, the Company calculated the weighted average closing price for the trailing 10-day period with trades that ended on the balance sheet date.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Three Months<br/> Ended <br/> March 31,<br/> 2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Twelve Months<br/> Ended <br/> December 31,<br/> 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Beginning balance  Fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">27,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">(Gain) on derivatives resulting from change in fair value or extinguishment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(5,050)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(22,075)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Ending balance  Fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following table summarizes the modified option-pricing assumptions used: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Three Months <br/> Ended  <br/> March 31, <br/> 2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Twelve Months <br/> Ended <br/> December 31, <br/> 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">76-118</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.03-1.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.14-0.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.76

1.18

0.0103

0.0139

P1M20D

P10M20D

P0Y

2018-02-20

3108538

1.78

2024-10-14

40000000

1954388

41.0412949

100000

53369

2190330 1.87375

7760000

3108538

7800000

0.75

7100000

1.78

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Months Ended<br/> March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Employee and director stock option grants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">34,127</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16,648</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">139,311</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">149,026</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Total stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">173,438</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">165,674</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1448945

1227485

6.5

346898

615947

9704

278499

11787470

509392

8760446

508733

9269179

8.40

615947

286668

13199477

P7Y9M

380000

93332

286668

480000

2.10

P3Y

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Goodwill</font></i></b> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Goodwill is not amortized but is required to be evaluated for impairment annually or whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company evaluates goodwill for impairment annually in the fourth fiscal quarter and additionally on an interim basis if an event occurs or there is a change in circumstances, such as a decline in the Company’s stock price or a material adverse change in the business climate, which would more likely than not reduce the fair value of the reporting unit below its carrying amount. No such event or change in circumstances occurred; therefore, no changes in goodwill were made during the three months ended March 31, 2018 and 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill. The standard streamlines the methodology for calculating whether goodwill is impaired based upon whether the carrying amount of goodwill exceeds the reporting unit’s fair value. ASU 2017-04 applies to public business entities and those other entities that have goodwill reported in their financial statements and have not elected the private company alternative for the subsequent measurement of goodwill and is effective for annual and interim reporting periods beginning after December 15, 2019, with early adoption permitted. The Company does not expect that the adoption of this standard will have a material effect on its financial statements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Stock-Based Compensation</font></i></b> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for awards that are not performance-based is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Awards of stock that are not performance-based are valued at the fair market value on the date of the grant and are amortized over the service period of the award. Non-employee stock-based compensation is accounted for in accordance with the guidance of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) Topic 505, <i> Equity. </i> As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Derivative Instruments</font></i></b> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks.  However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities.  In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain a certain type of cash settlement feature, “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was 494,315 and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 533,065</font> at March 31, 2018 and December 31, 2017 respectively. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock.  Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At March 31, 2018 and December 31, 2017, these warrants represented the only outstanding derivative instruments issued or held by the Company.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Leases</font></i></b> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for in a similar fashion to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is currently evaluating the method of adoption and the impact of adopting ASU 2016-02 on its results of operations, cash flows and financial position.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Recent Accounting Pronouncements -</font></i></b> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">In July 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-11, <i>Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815).</i> The amendments in Part I of this update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is currently evaluating the method of adoption and the impact of adopting ASU 2017-11 on its results of operations, cash flows and financial position.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>4. STOCK-BASED COMPENSATION</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>Accounting for Stock-Based Compensation</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the three months ended March 31, 2018 there were no option grants issued. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Months Ended<br/> March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Employee and director stock option grants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">34,127</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16,648</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">139,311</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">149,026</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Total stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">173,438</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">165,674</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>Assumptions Used in Determining Fair Value</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Valuation and amortization method</i>. The fair value of each stock award is estimated on the grant date using the Black-Scholes option-pricing model.  The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. The estimated fair value of the non-employee options is amortized to expense over the period during which a non-employee is required to provide services for the award (usually the vesting period).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Volatility.</i> The Company estimates volatility based on an average of (1) the Company’s historical volatility since its common stock has been publicly traded and (2) review of volatility estimates of publicly held drug development companies with similar market capitalizations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Risk-free interest rate</i>. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Expected term</i>. The expected term of stock options granted is based on an estimate of when options will be exercised in the future. The Company applied the simplified method of estimating the expected term of the options, as described in the SEC’s Staff Accounting Bulletins 107 and 110, as the historical experience is not indicative of the expected behavior in the future. The expected term, calculated under the simplified method, is applied to groups of stock options that have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. The Company applied the simplified method to non-employees who have a truncation of term based on termination of service and utilizes the contractual life of the stock options granted for those non-employee grants which do not have a truncation of service.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Forfeitures.</i> The Company records stock-based compensation expense only for those awards that are expected to vest. A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. An annual forfeiture rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2</font></font>% was applied to all unvested options for employees and directors, respectively, for the three months ended March 31, 2018 and for the year ended December 31, 2017.  Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> There were no stock option grants during the three months ended March 31, 2018.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>Stock Option Activity</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number of <br/> Shares Issuable <br/> Upon Exercise <br/> of Outstanding <br/> Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Remaining<br/> Contracted<br/> Term in<br/> Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate <br/> Intrinsic <br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Outstanding at December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">531,729</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.55</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(4,350)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">48.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(17,987)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">509,392</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Exercisable, March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">278,499</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Unvested, March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">230,893</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8.48</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the estimated per-share fair value of common stock at the end of the respective period and the exercise price of the underlying options.  There have been no option exercises to date. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> As of March 31, 2018, there was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,023,289</font> of total unrecognized compensation cost related to unvested stock-based compensation arrangements.  Of this total amount, the Company expects to recognize approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">489,116</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">462,703</font>, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">71,470</font> during 2018, 2019, and 2020, respectively. The Company’s expense estimates are based upon the expectation that all unvested options will vest in the future, less the forfeiture rate discussed above. The weighted-average grant-date fair value of vested and unvested options outstanding at March 31, 2018 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.67</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.18</font>, respectively.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Restricted Stock Grant</i>s. During 2017, the Company granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 480,000</font> shares of restricted common stock with a weighted average grant date fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.10</font>. The shares vest annually over a three year period. As of December 31, 2017 <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 380,000</font> shares of restricted common stock were outstanding. There were no restricted stock grants issued during the three months ended March 31, 2018. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of restricted stock activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Outstanding at December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">380,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(93,332)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">286,668</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

55000

533065

55000

462703 71470

10061421

11444619

6875163

11238394

EX-101.SCH 6 clrb-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - FAIR VALUE link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - NOTES PAYABLE link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - NET LOSS PER SHARE link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Policies) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Details Textual) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - FAIR VALUE (Details) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - FAIR VALUE (Details 1) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - FAIR VALUE (Details 2) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - FAIR VALUE (Details Textual) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - STOCKHOLDERS' EQUITY (Details Textual) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - STOCK-BASED COMPENSATION (Details 1) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - STOCK-BASED COMPENSATION (Details 2) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - STOCK-BASED COMPENSATION (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - NOTES PAYABLE (Details Textual) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - NET LOSS PER SHARE (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 clrb-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 clrb-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 clrb-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Debt Disclosure [Abstract] Long-term Debt [Text Block] Notes Payable Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Text Block] Earnings Per Share [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Consolidation, Policy [Policy Text Block] Consolidation, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Share-Based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Fair Value Of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Derivatives, Policy [Policy Text Block] Derivatives, Policy [Policy Text Block] Statement Of Financial Position [Abstract] Statement [Table] Scenario [Axis] Scenario, Unspecified [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] CURRENT ASSETS: Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Restricted Cash and Cash Equivalents Restricted cash Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total FIXED ASSETS, NET Fixed assets, net Goodwill GOODWILL Other Assets Noncurrent OTHER ASSETS Liabilities and Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities, Current [Abstract] CURRENT LIABILITIES: Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued liabilities Derivative Liability, Current Derivative liability Deferred Rent Credit, Current Deferred rent Capital Lease Obligations, Current Capital lease obligations, current portion Liabilities Noncurrent [Abstract] LONG-TERM LIABILITIES: Capital Lease Obligations, Noncurrent Capital lease obligation, less current portion Liabilities, Noncurrent, Total Total long-term liabilities Liabilities, Total TOTAL LIABILITIES Commitments and Contingencies COMMITMENTS AND CONTINGENCIES (Note 8) Stockholders Equity [Abstract] STOCKHOLDERS’ EQUITY: Preferred Stock Value Preferred stock, $0.00001 par value; 7,000 shares authorized; Series B preferred stock; 11.5 and 18 issued and outstanding as of March 31, 2018 and December 31, 2017 respectively Common Stock, Value, Issued Common stock, $0.00001 par value; 80,000,000 shares authorized; 17,101,676 and 16,661,446 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively Additional Paid in Capital, Total Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders Equity Attributable to Parent, Total Total stockholders’ equity BALANCE BALANCE Liabilities and Equity, Total TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Fair Value Disclosures [Abstract] Fair Value, Liabilities Measured On Recurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Equity [Abstract] Schedule Of Stockholders' Equity Note, Warrants Or Rights [Table Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule Of Compensation Cost For Share-Based Payment Arrangements, Allocation Of Share-Based Compensation Costs By Plan [Table Text Block] Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule Of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Private Placement [Axis] Certificates of Deposit, at Carrying Value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Equity Components [Axis] Equity Component [Domain] February 2013 Public Offering Warrants [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Liabilities [Abstract] Liabilities: Range [Axis] Range [Domain] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares) Class of Warrant or Right [Table] November 2016 Public Offering Series C [Member] April 2016 Underwritten Registered Series A [Member] October 2015 Incremental Series A [Member] October 2015 Private Placement Series A [Member] October 2015 Offering - Placement Agent [Member] August 2014 Public Offering [Member] Consolidation Items [Axis] Consolidation Items [Domain] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Domain] Debt Instrument [Axis] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise Price (in dollars per share) Warrants Expiration Date Warrants Expiration Date Expiry date of warrants held. Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, issued Preferred Stock Shares Outstanding Preferred stock, outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock [Member] Debt Instrument, Name [Domain] Affiliation with Entity [Axis] Property, Casualty Insurance Underwriters, Affiliation with Registrant [Domain] Stock Issued During Period, Shares, New Issues Issuance of common stock and warrants, net of issuance costs (in shares) Line of Credit Facility [Table] Credit Facility [Axis] Credit Facility [Domain] Secured Debt [Member] Department [Axis] Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table] Option Indexed to Issuers Equity, Type [Axis] Option Indexed to Issuers Equity, Type [Domain] Employee and Director Stock Option [Member] Employee and director stock option grants [Member] Employee and director stock option member Income Statement Location [Axis] Income Statement Location [Domain] Research and Development Expense [Member] Research and development [Member] General and Administrative Expense [Member] General and administrative [Member] Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items] Share-based Compensation, Total Total stock-based compensation Stock-based compensation expense Schedule of Share-based Compensation, Stock Options, Activity [Table] Share-based Compensation, Stock Options, Activity [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Granted - Number of Shares Issuable Upon Exercise of Outstanding Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Expired- Number of Shares Issuable Upon Exercise of Outstanding Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period Forfeited - Number of Shares Issuable Upon Exercise of Outstanding Options Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercisable, Number Exercisable - Number of Shares Issuable Upon Exercise of Outstanding Options Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Unvested Outstanding Number Unvested - Number of Shares Issuable Upon Exercise of Outstanding Options The number of unvested equity-based payment instruments, including stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Outstanding - Weighted Average Exercise Price (in dollars per share) Outstanding - Weighted Average Exercise Price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average exercise price Granted - Weighted Average Exercise Price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Expired- Weighted Average Exercise Price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited - Weighted Average Exercise Price (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable - Weighted Average Exercise Price (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Exercisable Weighted Average Exercise Price Unvested - Weighted Average Exercise Price (in dollars per share) As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are non vested. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable - Weighted Average Remaining Contracted Term in Years Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Title of Individual [Axis] Relationship to Entity [Domain] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Award Type [Axis] Equity Award [Domain] Option Indexed to Issuers Equity [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Employee Service Share Based Compensation Nonvested Total Compensation In Current Year Employee Service Share Based Compensation Nonvested Total Compensation In Current Year Aggregate value for unrecognized compensation cost related to the unvested stock-based compensation arrangements in current year. Employee Service Share Based Compensation Nonvested Total Compensation In Year Two Aggregate value for unrecognized compensation cost related to the unvested stock-based compensation arrangements in year two. Employee Service Share Based Compensation Nonvested Total Compensation In Year Three Employee Service Share Based Compensation Nonvested Total Compensation In Year Three Aggregate value for unrecognized compensation cost related to the unvested stock-based compensation arrangements in year three. Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested and Expected To Vest Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award Options Unvested and Expected To Vest Outstanding Number (in shares) Number of outstanding options Unvested and expected to vest held by the Employee Stock Option Plan as of the balance sheet date. Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Warrants [Member] Equity Option [Member] Stock options [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Convertible Debt [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Income Statement [Abstract] Operating Costs and Expenses [Abstract] COSTS AND EXPENSES: Research and Development Expense, Total Research and development General and Administrative Expense, Total General and administrative Costs and Expenses, Total Total costs and expenses Operating Income (Loss), Total LOSS FROM OPERATIONS Operating Income (Loss) Nonoperating Income Expense [Abstract] OTHER INCOME (EXPENSE): Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Loss on revaluation of derivative warrants Loss on revaluation of derivative warrants (Gain) on derivatives resulting from change in fair value or extinguishment Interest Income (Expense), Nonoperating, Net Interest income, net Nonoperating Income (Expense), Total Total other income (expense), net Net Income (Loss) Attributable to Parent, Total Net Income (Loss) Attributable to Parent, Total NET LOSS Net loss Net loss Earnings Per Share, Basic and Diluted, Total BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE Weighted Average Number Of Shares Outstanding, Basic and Diluted SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE Statement Of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to cash used in operating activities: Depreciation, Depletion and Amortization, Total Depreciation and amortization EX-101.PRE 10 clrb-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2018	May 07, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Entity Registrant Name	Cellectar Biosciences, Inc.
Entity Central Index Key	0001279704
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CLRB
Entity Common Stock, Shares Outstanding		17,388,344

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 6,820,163	$ 10,006,421
Restricted cash	55,000	55,000
Prepaid expenses and other current assets	770,012	877,996
Total current assets	7,645,175	10,939,417
FIXED ASSETS, NET	228,836	244,713
GOODWILL	1,675,462	1,675,462
OTHER ASSETS	11,872	11,872
TOTAL ASSETS	9,561,345	12,871,464
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	1,883,783	1,867,758
Derivative liability	132,000	105,050
Deferred rent	88,964	138,944
Capital lease obligations, current portion	3,119	3,036
Total current liabilities	2,107,866	2,114,788
LONG-TERM LIABILITIES:
Capital lease obligation, less current portion	1,402	2,213
Total long-term liabilities	1,402	2,213
TOTAL LIABILITIES	2,109,268	2,117,001
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.00001 par value; 7,000 shares authorized; Series B preferred stock; 11.5 and 18 issued and outstanding as of March 31, 2018 and December 31, 2017 respectively	637,017	995,782
Common stock, $0.00001 par value; 80,000,000 shares authorized; 17,101,676 and 16,661,446 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	171	167
Additional paid-in capital	94,640,028	94,107,830
Accumulated deficit	(87,825,139)	(84,349,316)
Total stockholders’ equity	7,452,077	10,754,463
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 9,561,345	$ 12,871,464

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	7,000	7,000
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	17,101,676	16,661,446
Common stock, shares outstanding	17,101,676	16,661,446
Series B Preferred Stock [Member]
Preferred stock, issued	11.5	18
Preferred stock, outstanding	11.5	18

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
COSTS AND EXPENSES:
Research and development	$ 2,124,060	$ 1,856,880
General and administrative	1,329,467	955,356
Total costs and expenses	3,453,527	2,812,236
LOSS FROM OPERATIONS	(3,453,527)	(2,812,236)
OTHER INCOME (EXPENSE):
Loss on revaluation of derivative warrants	(26,950)	(82,475)
Interest income, net	4,654	3,387
Total other income (expense), net	(22,296)	(79,088)
NET LOSS	$ (3,475,823)	$ (2,891,324)
BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE	$ (0.21)	$ (0.24)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE	16,808,189	12,010,284

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,475,823)	$ (2,891,324)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	17,301	86,911
Stock-based compensation expense	173,438	165,674
Loss on revaluation of derivative warrants	26,950	82,475
Changes in:
Accounts payable and accrued liabilities	16,025	(230,341)
Prepaid expenses and other current assets	107,984	(199,616)
Other assets and liabilities	(49,980)	(1,216)
Cash used in operating activities	(3,184,105)	(2,987,437)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of fixed assets	(1,425)	(66,301)
Cash used in investing activities	(1,425)	(66,301)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of warrants	0	2,934,759
Payments on notes payable	0	(86,591)
Payments on capital lease obligations	(728)	(655)
Cash (used in) provided by financing activities	(728)	2,847,513
NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(3,186,258)	(206,225)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT BEGINNING OF PERIOD	10,061,421	11,444,619	$ 11,444,619
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF PERIOD	6,875,163	11,238,394	$ 10,061,421
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest expense	$ 0	$ 364

XML 16 R6.htm IDEA: XBRL DOCUMENT

NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature Of Business Organization and Going Concern Disclosure [Text Block]

1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN

XML 17 R7.htm IDEA: XBRL DOCUMENT

FAIR VALUE

3 Months Ended

Mar. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

2. FAIR VALUE

	⋅	Level 1: Input prices quoted in an active market for identical financial assets or liabilities.
	⋅	Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets, and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.
	⋅	Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.

	March 31, 2018
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
August 2014 Warrants	$	—	$	132,000	$	—	$	132,000
Total	$	—	$	132,000	$	—	$	132,000

	December 31, 2017
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	5,050	$	5,050
August 2014 Warrants		—		100,000		—		100,000
Total	$	—	$	100,000	$	5,050	$	105,050

The following table summarizes the modified option-pricing assumptions used:

	Three Months Ended March 31, 2018		Twelve Months Ended December 31, 2017
Volatility		N/A		76-118	%
Risk-free interest rate		N/A		1.03-1.39	%
Expected life (years)		N/A		0.14-0.89
Dividend		N/A		0	%

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.

	Three Months Ended March 31, 2018		Twelve Months Ended December 31, 2017
Beginning balance – Fair value	$	5,050	$	27,125
(Gain) on derivatives resulting from change in fair value or extinguishment		(5,050)		(22,075)
Ending balance – Fair value	$	—	$	5,050

To estimate the fair value of the August 2014 Warrants, the Company calculated the weighted average closing price for the trailing 10-day period with trades that ended on the balance sheet date.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 18 R8.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2018

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

3. STOCKHOLDERS’ EQUITY

Authorized Share Increase

October 2017 Registered Direct Offering

Common Stock Warrants

The following table summarizes information with regard to outstanding warrants to purchase common stock as of March 31, 2018.

Offering	Number of Shares Issuable Upon Exercise of Outstanding Warrants		Exercise Price		Expiration Date

October 2017 Series D Warrants		3,108,538	$	1.78	October 14, 2024
November 2016 Public Offering Series C		4,157,850	$	1.50	November 29, 2021
April 2016 Underwritten Registered Series A		3,626,942	$	3.04	April 20,2021
October 2015 Incremental Series A		300,006	$	2.13	October 20,2021
October 2015 Private Placement Series A		86,365	$	2.13	April 1, 2021
October 2015 Offering – Placement Agent		3,750	$	28.30	October 1, 2020
August 2014 Public Offering ⁽¹⁾		504,019	$	46.80	August 20, 2019
Total		11,787,470

(1)

XML 19 R9.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION

3 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

4. STOCK-BASED COMPENSATION

Accounting for Stock-Based Compensation

	Three Months Ended March 31,
	2018		2017

Employee and director stock option grants:
Research and development	$	34,127	$	16,648
General and administrative		139,311		149,026
Total stock-based compensation	$	173,438	$	165,674

Assumptions Used in Determining Fair Value

Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.

There were no stock option grants during the three months ended March 31, 2018.

Stock Option Activity

A summary of stock option activity is as follows:

	Number of Shares Issuable Upon Exercise of Outstanding Options		Weighted Average Exercise Price		Weighted Average Remaining Contracted Term in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2017		531,729	$	6.55
Granted		—	$	—
Expired		(4,350)	$	48.57
Forfeited		(17,987)	$	1.89
Outstanding at March 31, 2018		509,392	$	6.36

Exercisable, March 31, 2018		278,499	$	8.40		7.75	$	—
Unvested, March 31, 2018		230,893	$	3.89		8.48	$	—

Outstanding at December 31, 2017		380,000
Granted		—
Vested		(93,332)
Outstanding at March 31, 2018		286,668

XML 20 R10.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Notes Payable Disclosure [Text Block]

5. NOTES PAYABLE

XML 21 R11.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

Mar. 31, 2018

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

6. INCOME TAXES

XML 22 R12.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

7. NET LOSS PER SHARE

The following potentially dilutive securities have been excluded from the computation of diluted net income (loss) per share since their inclusion would be antidilutive:

	Three Months Ended March 31,
	2018		2017
Warrants		11,787,470		8,760,446
Preferred shares as converted into common stock		615,947		—
Stock options		509,392		508,733
Non-vested restricted stock		286,668		—
Total potentially dilutive shares		13,199,477		9,269,179

XML 23 R13.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

8. COMMITMENTS AND CONTINGENCIES

XML 24 R14.htm IDEA: XBRL DOCUMENT

NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Policies)

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Consolidation, Policy [Policy Text Block]

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Fair Value of Financial Instruments, Policy [Policy Text Block]

Derivatives, Policy [Policy Text Block]

Lessor, Leases [Policy Text Block]

New Accounting Pronouncements, Policy [Policy Text Block]

XML 25 R15.htm IDEA: XBRL DOCUMENT

FAIR VALUE (Tables)

3 Months Ended

Mar. 31, 2018

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

	March 31, 2018
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
August 2014 Warrants	$	—	$	132,000	$	—	$	132,000
Total	$	—	$	132,000	$	—	$	132,000

	December 31, 2017
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
February 2013 Public Offering Warrants	$	—	$	—	$	5,050	$	5,050
August 2014 Warrants		—		100,000		—		100,000
Total	$	—	$	100,000	$	5,050	$	105,050

Schedule Of Changes In Fair Value Warrants Classified Level Three [Table Text Block]

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.

	Three Months Ended March 31, 2018		Twelve Months Ended December 31, 2017
Beginning balance – Fair value	$	5,050	$	27,125
(Gain) on derivatives resulting from change in fair value or extinguishment		(5,050)		(22,075)
Ending balance – Fair value	$	—	$	5,050

2013 Warrants [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

The following table summarizes the modified option-pricing assumptions used:

	Three Months Ended March 31, 2018		Twelve Months Ended December 31, 2017
Volatility		N/A		76-118	%
Risk-free interest rate		N/A		1.03-1.39	%
Expected life (years)		N/A		0.14-0.89
Dividend		N/A		0	%

XML 26 R16.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2018

Equity [Abstract]

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

The following table summarizes information with regard to outstanding warrants to purchase common stock as of March 31, 2018.

Offering	Number of Shares Issuable Upon Exercise of Outstanding Warrants		Exercise Price		Expiration Date

October 2017 Series D Warrants		3,108,538	$	1.78	October 14, 2024
November 2016 Public Offering Series C		4,157,850	$	1.50	November 29, 2021
April 2016 Underwritten Registered Series A		3,626,942	$	3.04	April 20,2021
October 2015 Incremental Series A		300,006	$	2.13	October 20,2021
October 2015 Private Placement Series A		86,365	$	2.13	April 1, 2021
October 2015 Offering – Placement Agent		3,750	$	28.30	October 1, 2020
August 2014 Public Offering ⁽¹⁾		504,019	$	46.80	August 20, 2019
Total		11,787,470

(1)

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:

	Three Months Ended March 31,
	2018		2017

Employee and director stock option grants:
Research and development	$	34,127	$	16,648
General and administrative		139,311		149,026
Total stock-based compensation	$	173,438	$	165,674

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

A summary of stock option activity is as follows:

	Number of Shares Issuable Upon Exercise of Outstanding Options		Weighted Average Exercise Price		Weighted Average Remaining Contracted Term in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2017		531,729	$	6.55
Granted		—	$	—
Expired		(4,350)	$	48.57
Forfeited		(17,987)	$	1.89
Outstanding at March 31, 2018		509,392	$	6.36

Exercisable, March 31, 2018		278,499	$	8.40		7.75	$	—
Unvested, March 31, 2018		230,893	$	3.89		8.48	$	—

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of restricted stock activity is as follows:

Outstanding at December 31, 2017		380,000
Granted		—
Vested		(93,332)
Outstanding at March 31, 2018		286,668

XML 28 R18.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following potentially dilutive securities have been excluded from the computation of diluted net income (loss) per share since their inclusion would be antidilutive:

	Three Months Ended March 31,
	2018		2017
Warrants		11,787,470		8,760,446
Preferred shares as converted into common stock		615,947		—
Stock options		509,392		508,733
Non-vested restricted stock		286,668		—
Total potentially dilutive shares		13,199,477		9,269,179

XML 29 R19.htm IDEA: XBRL DOCUMENT

NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Certificates of Deposit, at Carrying Value	$ 55,000		$ 55,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	494,315		533,065
Operating Income (Loss)	$ (3,453,527)	$ (2,812,236)

XML 30 R20.htm IDEA: XBRL DOCUMENT

FAIR VALUE (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Liabilities:
Derivative Liability, Current	$ 132,000	$ 105,050
February 2013 Public Offering Warrants [Member]
Liabilities:
Derivative Liability, Current		5,050
August 2014 Warrants [Member]
Liabilities:
Derivative Liability, Current	132,000	100,000
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Derivative Liability, Current	0	0
Fair Value, Inputs, Level 1 [Member] \| February 2013 Public Offering Warrants [Member]
Liabilities:
Derivative Liability, Current		0
Fair Value, Inputs, Level 1 [Member] \| August 2014 Warrants [Member]
Liabilities:
Derivative Liability, Current	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Derivative Liability, Current	132,000	100,000
Fair Value, Inputs, Level 2 [Member] \| February 2013 Public Offering Warrants [Member]
Liabilities:
Derivative Liability, Current		0
Fair Value, Inputs, Level 2 [Member] \| August 2014 Warrants [Member]
Liabilities:
Derivative Liability, Current	132,000	100,000
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Derivative Liability, Current	0	5,050
Fair Value, Inputs, Level 3 [Member] \| February 2013 Public Offering Warrants [Member]
Liabilities:
Derivative Liability, Current		5,050
Fair Value, Inputs, Level 3 [Member] \| August 2014 Warrants [Member]
Liabilities:
Derivative Liability, Current	$ 0	$ 0

XML 31 R21.htm IDEA: XBRL DOCUMENT

FAIR VALUE (Details 1) - 2013 Warrants [Member]	3 Months Ended	12 Months Ended
FAIR VALUE (Details 1) - 2013 Warrants [Member]	Mar. 31, 2018	Dec. 31, 2017
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility
Risk-free interest rate
Expected life (years)	0 years
Dividend		0.00%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility		118.00%
Risk-free interest rate		1.39%
Expected life (years)		10 months 20 days
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility		76.00%
Risk-free interest rate		1.03%
Expected life (years)		1 month 20 days

XML 32 R22.htm IDEA: XBRL DOCUMENT

FAIR VALUE (Details 2) - USD ($)	3 Months Ended		12 Months Ended
FAIR VALUE (Details 2) - USD ($)	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
(Gain) on derivatives resulting from change in fair value or extinguishment	$ (26,950)	$ (82,475)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance - Fair value	5,050	$ 27,125	$ 27,125
(Gain) on derivatives resulting from change in fair value or extinguishment	(5,050)		(22,075)
Ending balance - Fair value	$ 0		$ 5,050

XML 33 R23.htm IDEA: XBRL DOCUMENT

FAIR VALUE (Details Textual) - shares	1 Months Ended
FAIR VALUE (Details Textual) - shares	May 20, 2016	Feb. 20, 2014	Mar. 31, 2018	Aug. 31, 2014	Feb. 28, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			11,787,470
February 2013 Public Offering Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					82,500
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations		27,500
Number Of Warrants Exercised	16,250
Warrants Expiration Date	Feb. 20, 2018
February 2013 Public Offering Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Outstanding	38,750
August 2014 Public Offering Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				494,315

XML 34 R24.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details)

3 Months Ended

Mar. 31, 2018

$ / shares

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

11,787,470

November 2016 Public Offering Series C [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

4,157,850

Exercise Price (in dollars per share) | $ / shares

$ 1.5

Warrants Expiration Date

Nov. 29, 2021

April 2016 Underwritten Registered Series A [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

3,626,942

Exercise Price (in dollars per share) | $ / shares

$ 3.04

Warrants Expiration Date

Apr. 20, 2021

October 2015 Incremental Series A [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

300,006

Exercise Price (in dollars per share) | $ / shares

$ 2.13

Warrants Expiration Date

Oct. 20, 2021

October 2015 Private Placement Series A [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

86,365

Exercise Price (in dollars per share) | $ / shares

$ 2.13

Warrants Expiration Date

Apr. 01, 2021

October 2015 Offering - Placement Agent [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

3,750

Exercise Price (in dollars per share) | $ / shares

$ 28.3

Warrants Expiration Date

Oct. 01, 2020

August 2014 Public Offering [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

504,019

^[1]

Exercise Price (in dollars per share) | $ / shares

$ 46.8

^[1]

Warrants Expiration Date

Aug. 20, 2019

^[1]

October 2017 Series D Warrants [Member]

Class of Warrant or Right [Line Items]

Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)

3,108,538

Exercise Price (in dollars per share) | $ / shares

$ 1.78

Warrants Expiration Date

Oct. 14, 2024

[1]	These warrants have a certain type of cash settlement feature and they have been accounted for as derivative instruments as described in Note 1, with the exception of 9,704 warrants issued in August 2014.

XML 35 R25.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Textual) - USD ($)		3 Months Ended	12 Months Ended
STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	Oct. 12, 2017	Mar. 31, 2018	Dec. 31, 2017	Sep. 12, 2017	Aug. 31, 2014
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		11,787,470
Common Stock, Shares Authorized		80,000,000	80,000,000	40,000,000
Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion		346,898	1,227,485
Conversion of Stock, Shares Converted		6.5	23
Preferred Stock Shares Outstanding		11.5	18
Preferred Stock Convertible Beneficial Conversion Feature		$ 1,448,945
Convertible Preferred Stock, Shares Issuable upon Conversion		615,947
October 2017 Registered public offering [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Value, New Issues	$ 7,760,000
October 2017 Registered public offering [Member] \| Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues	41.0412949
Shares Issued, Price Per Share	$ 100,000
Convertible Preferred Stock, Shares Issued upon Conversion	53,369
Convertible Preferred Stock, Total Number of Shares Issued upon Conversion	2,190,330
August 2014 Underwritten Offering [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					9,704
Common Stock [Member] \| October 2017 Registered public offering [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues	1,954,388
Convertible Preferred Stock Conversion Price	$ 1.87375
Series D Warrants [Member] \| October 2017 Registered public offering [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	3,108,538
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.78
Stock Issued During Period On Exercise Of Warrants, Value	$ 7,800,000
Common Stock, Conversion Basis	0.75
Proceeds from Warrant Exercises	$ 7,100,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details) - USD ($)	3 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 173,438	$ 165,674
Employee and director stock option grants [Member] \| Research and development [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	34,127	16,648
Employee and director stock option grants [Member] \| General and administrative [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 139,311	$ 149,026

XML 37 R27.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 1)	3 Months Ended
STOCK-BASED COMPENSATION (Details 1)	Mar. 31, 2018 USD ($) $ / shares shares
Share-based Compensation, Stock Options, Activity [Line Items]
Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	531,729
Granted - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	0
Expired- Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	(4,350)
Forfeited - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	(17,987)
Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	509,392
Exercisable - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	278,499
Unvested - Number of Shares Issuable Upon Exercise of Outstanding Options \| shares	230,893
Outstanding - Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 6.55
Granted - Weighted Average Exercise Price (in dollars per share) \| $ / shares	0
Expired- Weighted Average Exercise Price (in dollars per share) \| $ / shares	48.57
Forfeited - Weighted Average Exercise Price (in dollars per share) \| $ / shares	1.89
Outstanding - Weighted Average Exercise Price (in dollars per share) \| $ / shares	6.36
Exercisable - Weighted Average Exercise Price (in dollars per share) \| $ / shares	8.40
Unvested - Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 3.89
Exercisable - Weighted Average Remaining Contracted Term in Years	7 years 9 months
Unvested - Weighted Average Remaining Contracted Term in Years	8 years 5 months 23 days
Exercisable - Aggregate Intrinsic Value (in dollars) \| $	$ 0
Unvested - Aggregate Intrinsic Value (in dollars) \| $	$ 0

XML 38 R28.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 2) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2018 shares
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Outstanding at December 31, 2017	380,000
Granted	0
Vested	(93,332)
Outstanding at March 31, 2018	286,668

XML 39 R29.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
STOCK-BASED COMPENSATION (Details Textual) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share Based Compensation Nonvested Total Compensation In Current Year	$ 489,116
Employee Service Share Based Compensation Nonvested Total Compensation In Year Two	462,703
Employee Service Share Based Compensation Nonvested Total Compensation In Year Three	$ 71,470
Share Based Compensation Arrangement By Share Based Payment Award Options Unvested and Expected To Vest Outstanding Number (in shares)	3.18
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 1,023,289
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	6.67
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		480,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 2.10
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	286,668	380,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years

XML 40 R30.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Textual)	Mar. 31, 2017 USD ($)
Secured Debt [Member]
Line of Credit Facility [Line Items]
Notes Payable, Noncurrent	$ 450,000

XML 41 R31.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Details) - Convertible Debt [Member] - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	13,199,477	9,269,179
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,787,470	8,760,446
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	509,392	508,733
Preferred shares as converted into common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	615,947	0
Non-vested restricted stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	286,668	0

EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 43 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 83 147 1 true 31 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.novelos.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.novelos.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Sheet http://www.novelos.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Statements 3 false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.novelos.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.novelos.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 106 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN Sheet http://www.novelos.com/role/NatureOfBusinessOrganizationAndGoingConcern NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN Notes 6 false false R7.htm 107 - Disclosure - FAIR VALUE Sheet http://www.novelos.com/role/FairValue FAIR VALUE Notes 7 false false R8.htm 108 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.novelos.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 8 false false R9.htm 109 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.novelos.com/role/StockbasedCompensation STOCK-BASED COMPENSATION Notes 9 false false R10.htm 110 - Disclosure - NOTES PAYABLE Notes http://www.novelos.com/role/NotesPayable NOTES PAYABLE Notes 10 false false R11.htm 111 - Disclosure - INCOME TAXES Sheet http://www.novelos.com/role/IncomeTaxes INCOME TAXES Notes 11 false false R12.htm 112 - Disclosure - NET LOSS PER SHARE Sheet http://www.novelos.com/role/NetLossPerShare NET LOSS PER SHARE Notes 12 false false R13.htm 113 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.novelos.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 114 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Policies) Sheet http://www.novelos.com/role/NatureOfBusinessOrganizationAndGoingConcernPolicies NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Policies) Policies 14 false false R15.htm 115 - Disclosure - FAIR VALUE (Tables) Sheet http://www.novelos.com/role/FairValueTables FAIR VALUE (Tables) Tables http://www.novelos.com/role/FairValue 15 false false R16.htm 116 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.novelos.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.novelos.com/role/StockholdersEquity 16 false false R17.htm 117 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.novelos.com/role/StockbasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.novelos.com/role/StockbasedCompensation 17 false false R18.htm 118 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.novelos.com/role/NetLossPerShareTables NET LOSS PER SHARE (Tables) Tables http://www.novelos.com/role/NetLossPerShare 18 false false R19.htm 119 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Details Textual) Sheet http://www.novelos.com/role/NatureOfBusinessOrganizationAndGoingConcernDetailsTextual NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Details Textual) Details http://www.novelos.com/role/NatureOfBusinessOrganizationAndGoingConcernPolicies 19 false false R20.htm 120 - Disclosure - FAIR VALUE (Details) Sheet http://www.novelos.com/role/FairValueDetails FAIR VALUE (Details) Details http://www.novelos.com/role/FairValueTables 20 false false R21.htm 121 - Disclosure - FAIR VALUE (Details 1) Sheet http://www.novelos.com/role/FairValueDetails1 FAIR VALUE (Details 1) Details http://www.novelos.com/role/FairValueTables 21 false false R22.htm 122 - Disclosure - FAIR VALUE (Details 2) Sheet http://www.novelos.com/role/FairValueDetails2 FAIR VALUE (Details 2) Details http://www.novelos.com/role/FairValueTables 22 false false R23.htm 123 - Disclosure - FAIR VALUE (Details Textual) Sheet http://www.novelos.com/role/FairValueDetailsTextual FAIR VALUE (Details Textual) Details http://www.novelos.com/role/FairValueTables 23 false false R24.htm 124 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://www.novelos.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://www.novelos.com/role/StockholdersEquityTables 24 false false R25.htm 125 - Disclosure - STOCKHOLDERS' EQUITY (Details Textual) Sheet http://www.novelos.com/role/StockholdersEquityDetailsTextual STOCKHOLDERS' EQUITY (Details Textual) Details http://www.novelos.com/role/StockholdersEquityTables 25 false false R26.htm 126 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.novelos.com/role/StockbasedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://www.novelos.com/role/StockbasedCompensationTables 26 false false R27.htm 127 - Disclosure - STOCK-BASED COMPENSATION (Details 1) Sheet http://www.novelos.com/role/StockbasedCompensationDetails1 STOCK-BASED COMPENSATION (Details 1) Details http://www.novelos.com/role/StockbasedCompensationTables 27 false false R28.htm 128 - Disclosure - STOCK-BASED COMPENSATION (Details 2) Sheet http://www.novelos.com/role/StockbasedCompensationDetails2 STOCK-BASED COMPENSATION (Details 2) Details http://www.novelos.com/role/StockbasedCompensationTables 28 false false R29.htm 129 - Disclosure - STOCK-BASED COMPENSATION (Details Textual) Sheet http://www.novelos.com/role/StockbasedCompensationDetailsTextual STOCK-BASED COMPENSATION (Details Textual) Details http://www.novelos.com/role/StockbasedCompensationTables 29 false false R30.htm 130 - Disclosure - NOTES PAYABLE (Details Textual) Notes http://www.novelos.com/role/NotesPayableDetailsTextual NOTES PAYABLE (Details Textual) Details http://www.novelos.com/role/NotesPayable 30 false false R31.htm 131 - Disclosure - NET LOSS PER SHARE (Details) Sheet http://www.novelos.com/role/NetLossPerShareDetails NET LOSS PER SHARE (Details) Details http://www.novelos.com/role/NetLossPerShareTables 31 false false All Reports Book All Reports clrb-20180331.xml clrb-20180331.xsd clrb-20180331_cal.xml clrb-20180331_def.xml clrb-20180331_lab.xml clrb-20180331_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 48 0001144204-18-027302-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-18-027302-xbrl.zip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